Laurence Catley
Impact in
- Hematology top 0.2%
- Multiple Myeloma Research and Treatments
- Oncology top 2%
- Peptidase Inhibition and Analysis
- Cancer Treatment and Pharmacology
Papers in
- Hematology 41
- Multiple Myeloma Research and Treatments 36
- Oncology 19
- Cancer Treatment and Pharmacology 8
- Peptidase Inhibition and Analysis 5
- Co-authors
- Kenneth C. AndersonTeru HideshimaDharminder ChauhanPaul G. RichardsonNikhil C. MunshiKlaus PodarConstantine S. MitsiadesRichard LeBlanc
- Journals
- Blood (30 papers)Cancer Research (5 papers)Molecular Cancer Therapeutics (3 papers)Leukemia (3 papers)British Journal of Haematology (2 papers)
- Partner nations
- United StatesAustraliaItaly
In The Last Decade
Laurence Catley
59 papers receiving 3.9k citations
Hit Papers
Peers
Comparison fields: 5 of 102
- Hematology 2.3k
- Oncology 1.4k
- Molecular Biology 2.9k
- Genetics 436
- Immunology 519
Countries citing papers authored by Laurence Catley
This map shows the geographic impact of Laurence Catley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Laurence Catley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Laurence Catley more than expected).
Fields of papers citing papers by Laurence Catley
This network shows the impact of papers produced by Laurence Catley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Laurence Catley. The network helps show where Laurence Catley may publish in the future.
Co-authors
The 25 scholars most cited alongside Laurence Catley, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2014 | 19 | |
| 2 | 2013 | 119 | |
| 3 | 2013 | 17 | |
| 4 | 2009 | 2 | |
| 5 | 2007 | 18 | |
| 6 | Pharmacodynamic profiling defines the significant biological activities of the novel proteasome inhibitor NPI-0052: Comparison with Velcade® (Bortezomib) | 2006 | 1 |
| 7 | 2006 | 79 | |
| 8 | 2005 | 132 | |
| 9 | 2005 | 36 | |
| 10 | 2005 | 1 | |
| 11 | 2004 | 51 | |
| 12 | 2004 | 59 | |
| 13 | 2004 | 26 | |
| 14 | 2004 | 10 | |
| 15 | Targeting mitochondria to overcome conventional and Bortezomib-resistance in multiple myeloma cells. | 2003 | 2 |
| 16 | 2003 | 130 | |
| 17 | 2003 | 29 | |
| 18 | 2003 | 124 | |
| 19 | 2002 | 30 | |
| 20 | A phase 1 study of oral CC5013, an immunomodulatory thalidomide (Thal) derivative, in patients with relapsed and refractory multiple myeloma (MM). | 2001 | 23 |
About Laurence Catley
Laurence Catley is a scholar working on Hematology, Oncology, Molecular Biology, Genetics and Pathology and Forensic Medicine, having authored 59 papers that have together received 4.0k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (36 papers), Ubiquitin and proteasome pathways (12 papers), Cancer therapeutics and mechanisms (9 papers), Cancer Treatment and Pharmacology (8 papers), Protein Degradation and Inhibitors (6 papers), Cancer Mechanisms and Therapy (6 papers), Histone Deacetylase Inhibitors Research (5 papers) and Peptidase Inhibition and Analysis (5 papers). The work is most often cited by research in Hematology (2.3k citations), Oncology (1.4k citations), Molecular Biology (2.9k citations), Genetics (436 citations) and Immunology (519 citations). Laurence Catley has collaborated with scholars based in United States, Australia and Italy. Frequent co-authors include Kenneth C. Anderson, Teru Hideshima, Dharminder Chauhan, Paul G. Richardson, Nikhil C. Munshi, Klaus Podar, Constantine S. Mitsiades, Richard LeBlanc, Robert Schlossman and Nicholas Mitsiades. Their work appears in journals such as Blood, Cancer Research, Molecular Cancer Therapeutics, Leukemia and British Journal of Haematology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.